News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GI Dynamics Announces New EndoBarrier® Data from Research with GlaxoSmithKline (GSK) Presented during Digestive Disease Week


5/5/2014 7:49:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced that new data from a study with GlaxoSmithKline (NYSE: GSK) on EndoBarrier® and its potential mechanism of action were presented at Digestive Disease Week 2014 (DDW) during an oral presentation titled, “Duodenal-jejunal Bypass Liner Increases Fasting and Postprandial Serum Levels of Bile Acids in Patients with Severe Obesity.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES